Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Company Analysis

GALT Insider Trading

GALECTIN THERAPEUTICS INC | Pharmaceutical Preparations

Comprehensive Trading Performance Summary

The investment history of corporate insiders at GALECTIN THERAPEUTICS INC provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Pharmaceutical Preparations sector.

Transactions on Chart

Open Full Chart
Filing Date Trade Date Reporting Person Relationship Type Price Qty Total, $ Owned After Change, %
2019-06-04 00:45 2019-05-31 CALLICUTT JACK W Officer - Chief Financial Officer BUY $4.28 2,354 $10,075 3,614 +186.8%
2019-06-04 00:42 2019-05-31 ELDRED KARY Director BUY $4.28 3,033 $12,981 44,415 +7.3%
2019-06-04 00:31 2019-05-31 FREEMAN KEVIN D Director BUY $4.28 9,136 $39,102 23,469 +63.7%
2019-06-04 00:29 2019-05-31 OMENN GILBERT S Director BUY $4.28 18,578 $79,514 66,769 +38.6%
2019-06-04 00:29 2019-05-31 LEWIS JOEL Director BUY $4.28 12,849 $54,994 78,649 +19.5%
2019-06-04 01:10 2019-05-31 Uihlein Richard E Director, 10% owner BUY $4.28 4,680,606 $20,032,994 27,710 +100.0%
2019-04-09 23:02 2019-04-09 Uihlein Richard E Director, 10% owner BUY $4.82 20,700 $99,851 2,628,489 +0.8%
2019-04-08 23:32 2019-04-05 LEWIS JOEL Director BUY $4.82 667 $3,214 65,800 +1.0%
2019-04-08 23:31 2019-04-05 Uihlein Richard E Director, 10% owner BUY $4.81 21,000 $100,972 2,607,789 +0.8%
2019-04-08 23:30 2019-04-05 FREEMAN KEVIN D Director BUY $4.73 500 $2,365 2,000 +33.3%
2019-02-26 00:38 2019-02-21 Rubin Marc Director OPT+S $6.02 51,185 $308,200 13,581 0.0%
2019-02-12 00:24 2019-02-07 LEWIS JOEL Director BUY $4.48 1,000 $4,484 65,133 +1.6%
2019-02-12 00:23 2019-02-08 FREEMAN KEVIN D Director BUY $4.29 1,500 $6,428 1,500 +100.0%
2019-02-05 00:30 2019-01-30 AMELIO GILBERT F Director SELL $5.00 30,000 $150,000 154,614 -16.3%
2019-01-31 01:31 2019-01-29 LEWIS JOEL Director BUY $4.81 1,000 $4,805 64,133 +1.6%
2019-01-31 01:31 2019-01-28 Uihlein Richard E Director, 10% owner BUY $4.87 51,500 $250,558 2,586,789 +2.0%
2018-09-26 14:59 2018-09-25 ELDRED KARY Director BUY $6.10 2,000 $12,200 41,382 +5.1%
2018-09-11 23:06 2018-09-07 OMENN GILBERT S Director SELL $6.02 19,370 $116,586 48,191 -28.7%
2018-09-06 23:24 2018-09-04 Rubin Marc Director OPT+S $6.58 11,900 $78,256 20,581 0.0%
2018-09-04 23:08 2018-08-30 Rubin Marc Director OPT+S $6.08 58,100 $353,312 26,481 0.0%
2018-06-27 00:34 2018-06-25 LEWIS JOEL Director BUY $7.06 1,000 $7,058 51,480 +2.0%
2018-06-21 23:18 2018-06-19 CALLICUTT JACK W Officer - Chief Financial Officer OPT+S $8.61 226,000 $1,946,018 1,260 0.0%
2018-06-20 19:12 2018-06-14 CZIRR JAMES C Director SELL $8.61 151,860 $1,306,801 2,649,786 -5.4%
2018-06-20 19:07 2018-06-14 10X Fund, L.P. 10% owner SELL $8.61 151,860 $1,306,801 2,649,786 -5.4%
2018-06-15 23:02 2018-06-13 TRABER PETER G Officer - President & CEO OPT+S $7.51 100,000 $751,000 107,333 0.0%
2018-06-15 02:32 2018-06-13 10X Fund, L.P. 10% owner SELL $7.17 208,140 $1,493,280 2,801,646 -6.9%
2018-06-15 02:30 2018-06-13 CZIRR JAMES C Director SELL $7.17 208,140 $1,493,280 2,801,646 -6.9%
2018-06-14 23:34 2018-06-12 CALLICUTT JACK W Officer - Chief Financial Officer OPT+S $7.01 9,294 $65,167 1,260 0.0%
2018-06-14 23:32 2018-06-12 Shlevin Harold H. Officer - Chief Operating Officer OPT+S $7.41 43,698 $323,986 0 0.0%
2018-06-13 01:30 2018-06-08 10X Fund, L.P. 10% owner SELL $5.88 110,000 $646,800 3,009,786 -3.5%
2018-06-13 01:30 2018-06-08 CZIRR JAMES C Director SELL $5.88 110,000 $646,800 3,009,786 -3.5%
2018-06-12 23:51 2018-06-08 TRABER PETER G Officer - President & CEO OPT+S $5.86 70,000 $409,997 107,333 0.0%
2018-06-12 23:50 2018-06-08 Shlevin Harold H. Officer - Chief Operating Officer OPT+S $5.84 115,054 $671,984 18,154 0.0%
2018-06-12 23:48 2018-06-08 CALLICUTT JACK W Officer - Chief Financial Officer OPT+S $5.85 120,000 $702,504 1,260 0.0%
2018-06-08 23:33 2018-06-06 Shlevin Harold H. Officer - Chief Operating Officer OPT+S $5.20 109,969 $572,026 53,914 0.0%
2018-06-06 23:31 2018-06-04 Shlevin Harold H. Officer - Chief Operating Officer OPT+S $5.15 20,831 $107,357 53,914 0.0%
2018-06-05 23:58 2018-06-01 CZIRR JAMES C Director SELL $5.12 50,000 $256,080 3,119,786 -1.6%
2018-06-05 23:51 2018-06-01 10X Fund, L.P. 10% owner SELL $5.12 50,000 $256,080 3,119,786 -1.6%
2018-06-04 23:56 2018-05-31 CALLICUTT JACK W Officer - Chief Financial Officer OPT+S $5.00 46,651 $233,255 1,260 0.0%
2018-06-04 23:51 2018-05-31 Shlevin Harold H. Officer - Chief Operating Officer OPT+S $5.06 119,200 $602,926 53,914 0.0%
2018-04-18 23:31 2018-04-16 ZUCCONI THEODORE DANIEL Director OPT+S $3.58 4,000 $14,320 1,083 0.0%
2018-04-06 23:33 2018-04-04 CALLICUTT JACK W Officer - Chief Financial Officer OPT+S $5.00 3,349 $16,745 1,260 0.0%
2018-02-02 16:25 2018-02-01 FREEMAN KEVIN D Director BUY $4.10 2,000 $8,191 16,000 +14.3%
2018-01-30 05:58 2018-01-25 CZIRR JAMES C Director SELL $5.43 244,444 $1,328,284 3,120,984 -7.3%
2018-01-30 05:58 2018-01-25 10X Fund, L.P. 10% owner SELL $5.43 244,444 $1,328,284 3,120,984 -7.3%
2017-12-08 22:26 2017-12-07 FREEMAN KEVIN D Director BUY $1.63 8,400 $13,662 28,043 +42.8%
2017-12-09 00:36 2017-12-08 Rubin Marc Director BUY $1.85 7,000 $12,972 55,581 +14.4%
2017-05-24 16:39 2017-05-23 ZUCCONI THEODORE DANIEL Director BUY $2.27 1,000 $2,270 1,083 +1,204.8%
2016-11-19 01:12 2016-04-19 10X Fund, L.P. 10% owner SELL $1.65 44,312 $73,252 3,260,697 -1.3%
2016-11-19 01:10 2016-04-19 CZIRR JAMES C Director SELL $1.65 44,312 $73,252 3,260,697 -1.3%
SHOW ENTRIES

How to Interpret $GALT Trades

Not every insider transaction in GALECTIN THERAPEUTICS INC is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $GALT shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.

Data Source & Accuracy for GALT

Insider activity data for GALECTIN THERAPEUTICS INC is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $GALT, allowing you to follow the capital of those with the most intimate knowledge of the company.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.